-
2024-513724-42-00
10
Medulloblastoma
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517295-37-00
5
low and intermediate risk neuroblastoma
-
2025-522377-12-00
5
metastatic colorectal cancer
-
2023-507600-32-00
5
2025-05-22
Pneumococcal Immunization
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-515646-16-00
4
2025-06-24
Recurrent, persistent, metastatic or locally advanced vulvar cancer
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer